[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100481795":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":35,"locations":44,"responsibleParty":68,"collaborators":26,"id":71,"slug":26,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":78,"sex":79,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":26,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":47,"whyStopped":26,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"Hvidovre University Hospital","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"ASTARTE™ oral capsule","ACTIVE_COMPARATOR","The capsule will contain a mixture of four probiotic strains with a combined potency of 5 x10\\^9 (CFU)\u002Fcapsule:\n\nLactobacillus crispatus LBV88, 2 x10\\^9 CFU\u002Fg Lactobacillus rhamnosus LBV96, 2 x10\\^9 CFU\u002Fg Lactobacillus gasseri LBV150N , 0.6 x10\\^9 CFU\u002Fg Lactobacillus jensenii LBV116, 0.4 x10\\^9 CFU\u002Fg Corn starch 79 mg, Magnesium salts of fatty acid 3 mg, Silicon dioxide 3 mg, Vegetal capsule size 1 DR white 75 mg, Fructooligosaccharides 30mg",[13,14],"Dietary Supplement: ASTARTE™ oral capsules","Dietary Supplement: Placebo oral capsules",{"label":16,"type":17,"description":18,"interventionNames":19},"Placebo oral capsule","PLACEBO_COMPARATOR","The placebo oral capsules is identical to the ASTARTE™ capsules and contains Corn starch 79 mg, Magnesium salts of fatty acid 3 mg, Silicon dioxide 3 mg, Vegetal capsule size 1 DR white 75 mg, Fructooligosaccharides 30mg",[13,14],[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DIETARY_SUPPLEMENT","ASTARTE™ oral capsules","1 Capsule daily for 6 months",[9,16],null,{"type":22,"name":28,"description":24,"armGroupLabels":29,"otherNames":26},"Placebo oral capsules",[9,16],[31],{"name":32,"affiliation":33,"role":34},"Andreas Petersen, DM. PhD","Hvidovre Hospital, University of Copenhagen","PRINCIPAL_INVESTIGATOR",[36,40],{"name":32,"role":37,"phone":38,"phoneExt":26,"email":39},"CONTACT","+4538626199","andreas.munk.petersen@regionh.dk",{"name":41,"role":37,"phone":42,"phoneExt":26,"email":43},"Khaled Ghathian, phd.stud.","+38623205","khaled.saoud.ali.ghathian@regionh.dk",[45],{"facility":46,"status":47,"city":48,"state":49,"zip":50,"country":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"Gastrounit, Copenhagen University Hospital Hvidovre","RECRUITING","Hvidovre","Copenhagen","2650","Denmark",{"type":53,"coordinates":54},"Point",[55,56],12.47708,55.64297,{"lat":56,"lon":55},[59,62,66],{"name":60,"role":37,"phone":61,"phoneExt":26,"email":39},"Andreas M Petersen, MD, ph.d","004538625960",{"name":63,"role":37,"phone":64,"phoneExt":26,"email":65},"Khaled Ghathian, ph.d. stud.","+4538623205","kgha0001@regionh.dk",{"name":67,"role":34,"phone":26,"phoneExt":26,"email":26},"Andreas M Petersen, MD, ph.d.",{"type":34,"investigatorFullName":69,"investigatorTitle":70,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Andreas Munk Petersen","MD, Associate Professor, PhD","100481795",false,"NCT05553652","The Effect of ASTARTE™ on Recurrent Urinary Tract Infection","The Effect of ASTARTE™; Lactobacillus Crispatus, Lactobacillus Rhamnosus, Lactobacillus Jenesii and Lactobacillus Gasseri on the Reduction of Risk Factors for Recurrent Urinary Tract Infection in Women","rUTI","Inclusion Criteria:\n\n* Women 18-40 years of age\n* Recurrent UTI (2 times UTI within 6 months or \\> 3 times UTI infection within one year).\n* The subjects should be informed about the trial protocol.\n* The subject must be able to follow the protocol, have provided voluntary consent and have signed the declaration of consent.\n\nExclusion Criteria:\n\n* Pregnancy or planning pregnancy\n* Breastfeeding\n* Participation in another trial with probiotic the last 30 days.\n* Hypersensitivity to any ingredient in the study product\n* Patients primarily admitted for a disorder other than UTI\n* Antibiotic treatment for any other condition than UTI at time of recruitment the last 30 days",true,"FEMALE","18 Years","40 Years",{"count":83,"type":84},720,"ESTIMATED","INTERVENTIONAL",[87],"NA","Investigate the effect of dietary supplements\u002Fprobiotic ASTARTE™ ( L. crispatus, L. rhamnosus, L. jensenii, L. gasseri) on the microbiome composition in the intestine and vagina and thereby a reduction of risk factors for the development of rUTI during 6 months of intervention in women aged 18-40 years. This is measured by the incidence of symptomatic UTI.",[90],"Recurrent Urinary Tract Infection",[76,92],"Probiotic","2022-09-21",{"date":95,"type":96},"2022-09-23","ACTUAL",{"date":98,"type":96},"2022-09-19",{"date":100,"type":84},"2027-12-01",{"name":5,"class":6},1]